This study is testing a treatment called rapcabtagene autoleucel for people with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA), which are types of ANCA-Associated Vasculitis (AAV). Rapcabtagene autoleucel is a type of CAR-T therapy, which uses your own modified immune cells. You might receive rapcabtagene autoleucel or a standard treatment. The study wants to see how well rapcabtagene autoleucel works and if it's safe, by measuring how long people live without certain events (Event-free survival). To join, you need to be between 18 and 75 years old, have a confirmed diagnosis of severe active GPA or MPA, and test positive for ANCA-autoantibodies. The study plans to enroll 126 participants.

Study design

This is a Phase 2, randomized study with an active control, meaning some participants will receive the study treatment and others will receive a standard treatment. It is assessor-blinded, so the people evaluating your health won't know which treatment you received.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants who receive rapcabtagene autoleucel will be followed for up to 15 years after their infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.